Figure 6
From: Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma
(A) Representative figures of apoptotic assays of various ES-2 transfectants treated with paclitaxel. (B) Representative figures of apoptotic assays of various ES-2 transfectants treated with cisplatin. ES2 cells without (a-d) or with (e-h) HIN-1 overexpression. The induction of apoptosis is indicated as black arrows in VL (panel e) and white arrows in the overlay (panel h). Late apoptosis is represented as yellow arrows in panel h. VL, visible light; PI, propidium iodide. Bar, 50 μm. (C) Caspase-3 activities of various ES-2 transfectants treated with paclitaxel. Increasing caspase-3 activities were shown by ES-2 HIN-1 transfectants compared to EV-transfected ES-2 cells, when treated with paclitaxel. (* p < 0.05) (D) Caspase-3 activities of various ES-2 transfectants treated with cisplatin. Increasing caspase-3 activities were shown by ES-2 HIN-1 transfectants compared to EV-transfected ES-2 cells, when treated with cisplatin (* p < 0.05, ** p < 0.001). (E) Akt Phosphorylation in HIN-1-overexpressed ES-2 cells. Western blots for phospho-Akt (p-Akt) and total-Akt (t-Akt) were prepared from ES-2 cells treated with 15 nM paclitaxel for 0 h, 1 h, 3 h, 6 h, or 24 h. A marked decrease of p-Akt (Thr308) was observed. α-tubulin was as a loading control.